Avalo Therapeutics, Inc. (AVTX)
| Market Cap | 968.26M +1,769.2% |
| Revenue (ttm) | 59,000 -86.6% |
| Net Income | -84.74M |
| EPS | -5.36 |
| Shares Out | 52.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 835,800 |
| Open | 19.05 |
| Previous Close | 18.91 |
| Day's Range | 18.34 - 19.12 |
| 52-Week Range | 4.72 - 24.27 |
| Beta | 0.79 |
| Analysts | Strong Buy |
| Price Target | 44.69 (+142.62%) |
| Earnings Date | Aug 6, 2026 |
About AVTX
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1β-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1β, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Financial Performance
In 2025, Avalo Therapeutics's revenue was $59,000, a decrease of -86.62% compared to the previous year's $441,000. Losses were -$78.26 million, 122.8% more than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for AVTX stock is "Strong Buy." The 12-month stock price target is $44.69, which is an increase of 142.62% from the latest price.
News
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for...
Avalo Therapeutics initiated with an Outperform at Leerink
Leerink initiated coverage of Avalo Therapeutics (AVTX) with an Outperform rating and $38 price target With de-risked Phase 2 data in hand for abdakibart, the firm believes Avalo Therapeutics offers…
Avalo Therapeutics to join Russell 2000, Russell 3000
Avalo Therapeutics (AVTX) announced that it will be added to the small-cap Russell 2000 Index and the broad-market Russell 3000 Index, effective after the close of U.S. equity markets on…
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
WAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for...
Avalo Therapeutics Appoints Ron Philip to Board of Directors
WAYNE, Pa., June 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for...
Avalo Therapeutics advances AVTX-010
Avalo Therapeutics (AVTX) announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1beta monoclonal antibody with the potential for development in hidradenitis suppurativa as well ...
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
WAYNE, Pa., June 16, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated i...
Avalo Therapeutics initiated with a Buy at BofA
BofA initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and $35 price target The firm sees Avalo as a “cleaner, single-asset immunology story” after the positive Phase 2…
Avalo Therapeutics Transcript: AGM 2026
The meeting covered board introductions, voting on three key proposals, and outlined the agenda and rules. All director nominees were elected, the Employee Stock Purchase Plan amendment was approved, and the auditor was ratified. Final results will be published in a Form 8-K.
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated in...
Avalo Therapeutics price target lowered to $34 from $40 at Wedbush
Wedbush lowered the firm’s price target on Avalo Therapeutics (AVTX) to $34 from $40 and keeps an Outperform rating on the shares. The firm notes the company reported first quarter…
Avalo Therapeutics price target raised to $45 from $39 at Mizuho
Mizuho raised the firm’s price target on Avalo Therapeutics (AVTX) to $45 from $39 and keeps an Outperform rating on the shares post the Q1 report. The company continues to…
Avalo Therapeutics price target lowered to $35 from $40 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Avalo Therapeutics (AVTX) to $35 from $40 and keeps a Buy rating on the shares. The LOTUS results showed that abdakibart is…
Avalo Therapeutics price target lowered to $55 from $62 at Citizens
Citizens analyst Jason Butler lowered the firm’s price target on Avalo Therapeutics (AVTX) to $55 from $62 and keeps an Outperform rating on the shares. Positive Phase 2 LOTUS results…
Avalo Therapeutics reports Q1 EPS (98c), consensus ($1.01)
“The positive Phase 2 LOTUS trial results of abdakibart in HS, which demonstrated a deep and consistent clinical response across both HiSCR75 and HiSCR50 endpoints, mark the beginning of a…
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-m...
Avalo Therapeutics Earnings release: Q1 2026
Avalo Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Avalo Therapeutics Quarterly report: Q1 2026
Avalo Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Avalo Therapeutics price target raised to $60 from $48 at Piper Sandler
Piper Sandler raised the firm’s price target on Avalo Therapeutics (AVTX) to $60 from $48 and keeps an Overweight rating on the shares. The firm notes shares traded-up about 60%…
Avalo Therapeutics price target raised to $62 from $52 at Citizens
Citizens raised the firm’s price target on Avalo Therapeutics (AVTX) to $62 from $52 and keeps an Outperform rating on the shares. Avalo Therapeutics reported positive Phase 2 results for…
Avalo Therapeutics 19.73M share Spot Secondary priced at $17.75
The deal range was $17.25-$17.75. Leerink, TD Cowen and BofA acted as joint book running managers for the offering.
Avalo Therapeutics price target raised to $58 from $40 at BTIG
BTIG raised the firm’s price target on Avalo Therapeutics (AVTX) to $58 from $40 and keeps a Buy rating on the shares. The firm is citing the company’s announcement of…
Why Is Avalo Therapeutics Stock (AVTX) Up Today?
Avalo Therapeutics stock was up on Wednesday alongside a public offering.
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-m...
Avalo Therapeutics announces common stock and warrants offering, no amount given
Avalo Therapeutics (AVTX) announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to…